A retrospective single center study to evaluate safety and efficacy of PD‐1 inhibitors (Toripalimab, Camrelizumab or Sintilimab) in hepatocellular carcinoma patients in a real-life Chinese cohort
Latest Information Update: 13 Jul 2020
At a glance
- Drugs Camrelizumab (Primary) ; Sintilimab (Primary) ; Toripalimab (Primary)
- Indications Liver cancer
- Focus Adverse reactions; Therapeutic Use
- 13 Jul 2020 New trial record
- 05 Jul 2020 Results published in the British Journal of Clinical Pharmacology